# Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

Study · id `cardio:ct-nct01587651` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01587651](<https://clinicaltrials.gov/study/NCT01587651>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01587651

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT01587651. Randomized; no masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-04-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Start date: 2012-03 (registry gives no type) (ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Results first posted: 2014-04-29 (ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Countries: United States; United Kingdom (ClinicalTrials.gov record NCT01587651, source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01587651-2019-01-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
- Acronym: SWAP-2
- Condition: Coronary Artery Disease
- Intervention (Drug): Prasugrel Loading Dose
- Intervention (Drug): Prasugrel Maintenance Dose
- Intervention (Drug): Ticagrelor Maintenance Dose
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: faf85fb1f2e319c6a124ca57c5ad5fa240f05201e05cd4ae4cbc3a6c9afc3ed8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
